From GlobeNewswire:

LumiraDx Limited (Nasdaq: LMDX) will face a suspension of trading on the Nasdaq Stock Market at the start of business on January 9, 2024 due to non-compliance with Nasdaq’s continued listing standards. After failing to maintain compliance with the minimum bid price requirement, a notification from Nasdaq’s Listing Qualifications Department on October 24, 2023 stated that the Company’s securities were subject to delisting. LumiraDx also announced the appointment of joint administrators for two of its subsidiaries and the sale of certain companies to Roche, prompting the Board of Directors to approve the withdrawal of the Company’s appeal. Nasdaq confirmed the withdrawal of its appeal on January 5, 2024, resulting in the pending suspension of trading.

LumiraDx Limited (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its highly accessible diagnostic solutions are built around actively controlled microfluidic technology, offering fast, high performance testing wherever the patient is. The Company supports both lab comparable tests on a single portable Platform and high-complexity laboratory testing in an accessible high-throughput format. Founded in 2014 and based in the UK, LumiraDx’s diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across various settings.



Read more: LumiraDx Announces its Securities will be Suspended from